{"entity":{"id":"nct07503756","kind":"trial","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of capecitabine, bevacizumab (glioblastoma use) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting.","summary":"JS212 Combination Therapies in Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07503756 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 80 participants, started 2026-04-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: JS212; Capecitabine; Bevacizumab; Oxaliplatin; JS207. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Investigator-assessed objective response rate (ORR); Safety and Tolerability(AEs); Safety and Tolerability(SAEs). Colorectal eligibility wording from the registry: \"* Adults aged 18-75 years with histologically confirmed metastatic colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07503756","url":"https://clinicaltrials.gov/study/NCT07503756"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["capecitabine","bevacizumab-glioma","folfox"],"companies":["junshi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07503756","phase":"2","setting":"An Open-label, Multicenter Phase 2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JS212 Combination Therapies in Patients With Metastatic Colorectal Cancer","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07503756/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"}],"company":[{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}